Overview / Abstract: |
Sara A. Hurvitz, MD, FACP, Director of the Breast Cancer Clinical Trials Program at the David Geffen School of Medicine at UCLA, and a prominent authority on TNBC, provides perspectives on personalized care plans for patients with metastatic TNBC, efficacy and safety of emerging treatments, strategies to improve quality of life for patients with metastatic TNBC, and much more! Start the activity now! STATEMENT OF NEED With an estimated 284,200 new cases per year, breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United States (ACS, 2021). Numerous subtypes of invasive breast cancers exist, including triple-negative breast cancer (TNBC), an aggressive subtype which accounts for approximately 15% of all cases. Without the expression of estrogen, progesterone, and human epidermal growth factor 2 (HER2) receptors, TNBC does not respond to hormone therapies or targeted agents, leading to limited treatment options and a poor prognosis compared with other types of invasive breast cancer. In addition, treatment planning can be complicated by individual patient characteristics, response to prior therapy, and cumulative doses and toxicity. With a dearth of effective treatment options, 5-year survival rates for TNBC range from 91% for localized disease to only 12% for distant disease (ACS, 2021). TARGET AUDIENCE Oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC). LEARNING OBJECTIVES Upon completion of this activity, participants should be able toEvaluate clinical and molecular factors that can inform personalized care plans for patients with metastatic TNBC |
Expiration |
Jul 22, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1.0 CME | 1.0 NCPD | MOC | ILNA |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Sara A. Hurvitz, MD, FACP |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Merck. |
Keywords / Search Terms |
i3 Health triple negative breast cancer, breast cancer, TNBC, metastatic triple negative breast cancer, oncology, i3 Health i3 Health , i3 Health i3 Health, live webinar, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME Free CE CME Live CE CME Free CE CME |